Press release
Graves' Disease Market New Product Development & Latest Trends
Graves' Disease Market
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overproduction of thyroid hormones, through antibodies that stimulate the thyroid gland. It is among the most common thyroid-related autoimmune conditions, disproportionately affecting women between 30-60 years of age. Beyond metabolic complications such as weight loss, heat intolerance, and palpitations, Graves' disease can cause thyroid eye disease (TED), which impairs vision and quality of life.
For decades, treatment has relied on antithyroid drugs, radioactive iodine therapy (RAI), and thyroidectomy. However, these conventional options often come with side effects or limited long-term effectiveness. In recent years, targeted biologics and immunotherapies, such as teprotumumab (Tepezza), have emerged as breakthrough options, reshaping the therapeutic landscape. Between 2024 and 2034, the Graves' disease market is poised for significant growth, supported by innovation in biologics, improved diagnostic capabilities, and greater awareness of autoimmune disorders.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72038
Market Overview
• Market Size 2024: USD 1.56 billion (estimated)
• Forecasted Market Size 2034: USD 2.82 billion
• CAGR (2024-2034): 6.1%
Key Highlights
• Rising incidence of autoimmune thyroid disorders globally.
• Strong uptake of teprotumumab (Horizon Therapeutics) for thyroid eye disease.
• Ongoing R&D into next-generation immunomodulatory drugs.
• Expanding healthcare access in Asia-Pacific fueling demand.
Segmentation Analysis
By Product
• Antithyroid drugs (methimazole, propylthiouracil)
• Radioactive iodine (RAI) therapy
• Surgical interventions (thyroidectomy)
• Biologics & monoclonal antibodies (teprotumumab, rituximab - pipeline)
• Beta-blockers and supportive drugs
By Platform
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
By Technology
• Pharmacological therapies
• Radiological treatment (RAI)
• Immunotherapy & biologics
• Combination approaches
By End Use
• Hospitals and specialty clinics
• Ambulatory surgical centers
• Homecare and outpatient settings
By Application
• Hyperthyroidism management
• Thyroid eye disease (TED)
• Cardiovascular complication management
• Pediatric and adult Graves' disease
Summary:
Antithyroid drugs and RAI therapy remain first-line treatments, but the biologics segment is expanding fastest, especially in TED management. Surgery is vital for refractory or severe cases, while beta-blockers continue to serve as supportive therapy.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72038/graves-disease-market
Regional Analysis
North America
• Largest share in 2024, driven by high diagnosis rates, strong healthcare infrastructure, and rapid uptake of biologics.
• U.S. adoption of Tepezza has transformed TED management.
Europe
• Established use of RAI and antithyroid drugs, with reimbursement frameworks supporting care.
• Germany, UK, and France lead in TED clinical trials.
Asia-Pacific
• Fastest-growing region (CAGR ~7.5%) due to large patient base, rising autoimmune disorder prevalence, and improving healthcare infrastructure.
• Japan and China advancing in early adoption of innovative therapies.
Middle East & Africa
• Growing burden of thyroid disorders but limited access to biologics.
• Reliance on generics and RAI therapy remains high.
Latin America
• Brazil and Mexico drive regional demand.
• Growing medical tourism for thyroid surgery contributes to expansion.
Summary:
North America dominates, but Asia-Pacific is set to post the strongest growth, supported by demographic trends, healthcare modernization, and broader patient access to diagnostics and advanced therapies.
Market Dynamics
Key Growth Drivers
• Rising prevalence of autoimmune thyroid disorders worldwide.
• Increased focus on thyroid eye disease (TED) management with biologics.
• Expanding healthcare infrastructure in emerging economies.
• Integration of digital health for endocrine monitoring.
Key Challenges
• High cost of biologics like teprotumumab limiting adoption in low-income regions.
• Side effects and recurrence rates of conventional therapies (RAI, surgery).
• Limited access to endocrinologists in rural or underserved areas.
• Lack of global standardization in treatment guidelines.
Latest Trends
• Development of next-generation biologics for TED with improved safety profiles.
• Growing use of personalized medicine approaches based on genetic and immunological data.
• Telemedicine and online pharmacies improving treatment access.
• Expansion of real-world evidence studies to support reimbursement of high-cost biologics.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72038
Competitor Analysis
Major Players
• Horizon Therapeutics plc (Tepezza - teprotumumab)
• Sanofi S.A.
• Novartis AG
• AbbVie Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd.
• Roche Holding AG
• Amgen Inc.
• GlaxoSmithKline plc
Summary:
The market is highly competitive, with Horizon dominating the TED biologics space, while established pharma companies continue leading in antithyroid drugs and RAI. Competitive strategies increasingly focus on immunotherapies and combination approaches for better disease management.
Conclusion
The Graves' disease market is projected to grow from USD 1.56 billion in 2024 to USD 2.82 billion by 2034, at a CAGR of 6.1%. The shift from conventional therapies toward biologics and immune-targeted treatments will redefine patient outcomes.
Key Takeaways:
• North America leads, but Asia-Pacific shows the highest growth potential.
• Antithyroid drugs and RAI remain essential, but biologics are revolutionizing TED care.
• High therapy costs and regional disparities remain barriers.
• Competition led by Horizon's Tepezza and innovation pipelines from major pharma players.
The next decade will see the Graves' disease market evolve from managing symptoms to targeted, personalized, and potentially disease-modifying therapies, offering patients improved quality of life and long-term remission.
This report is also available in the following languages : Japanese (バセドウ病市場), Korean (그레이브스병 시장), Chinese (格雷夫斯病市场), French (Marché de la maladie de Graves), German (Markt für Morbus Basedow), and Italian (Mercato della malattia di Graves), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72038
Our More Reports:
Hypercholesterolemia Market
https://exactitudeconsultancy.com/reports/71992/hypercholesterolemia-market
Gaucher's Disease Market
https://exactitudeconsultancy.com/reports/71990/gaucher-s-disease-market
Familial Hypercholesterolemia Market
https://exactitudeconsultancy.com/reports/71988/familial-hypercholesterolemia-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graves' Disease Market New Product Development & Latest Trends here
News-ID: 4188259 • Views: …
More Releases from Exactitude Consultancy
Underactive Bladder Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Underactive bladder (UAB) is a chronic, often underdiagnosed condition characterized by decreased detrusor muscle activity, leading to incomplete bladder emptying, infrequent urination, and urinary retention. While less recognized compared to overactive bladder (OAB), UAB has significant implications for patient quality of life, particularly among the elderly population. It is commonly associated with aging, diabetes, neurological disorders, pelvic surgeries, and chronic obstruction.
Historically, treatment options have been limited, focusing primarily on catheterization,…
Hereditary Hemochromatosis (HH) Market to Reach USD 5.1 Billion by 2034
Hereditary Hemochromatosis (HH) is a genetic disorder characterized by excessive absorption and storage of dietary iron, leading to iron overload in organs such as the liver, heart, and pancreas. Left untreated, HH can result in severe complications including cirrhosis, diabetes, cardiomyopathy, arthritis, and liver cancer. The condition is most often linked to mutations in the HFE gene, particularly the C282Y and H63D variants.
Download Full PDF Sample Copy of Market Report…
Heterozygous Familial Hypercholesterolemia (HeFH) Market to Reach USD 12 Billion …
Heterozygous Familial Hypercholesterolemia (HeFH) is a common yet underdiagnosed genetic disorder that significantly elevates low-density lipoprotein cholesterol (LDL-C) levels from birth. Affecting approximately 1 in 250 individuals worldwide, HeFH increases the risk of premature cardiovascular disease and heart attacks. Caused by mutations in genes such as LDLR, APOB, and PCSK9, HeFH requires lifelong management, typically with lipid-lowering therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72023
In recent years, the…
Homocystinuria Market to Reach USD 1.5 Billion by 2034
Homocystinuria is a rare inherited metabolic disorder caused by a deficiency of enzymes involved in the metabolism of the amino acid methionine, most commonly cystathionine beta-synthase (CBS). This results in elevated levels of homocysteine and its metabolites in blood and urine, leading to multisystem complications including skeletal abnormalities, intellectual disability, vascular disease, and ocular problems such as lens dislocation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72025
Although the disease…
More Releases for Graves
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graves Ophthalmopathy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Graves Ophthalmopathy Research. Learn more about…
Search for graves and burials in Minsk
If you are looking for information about the location of the grave in Minsk or other regions of Belarus, the company https://verimby.com +375293887408 (Viber); +375447498518 (WhatsApp) offers professional assistance in this important matter. We specialize in finding burial sites, providing detailed data and providing support in restoring lost ties with the past, creating a family tree, even if you are in another country.
Why can the search for graves in Belarus…
Graves' Disease Treatment Market Size, Drugs, Companies 2034 | DelveInsight
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and…
Japan Graves' disease Market Size & Growth Analysis Report, 2019-2025
Japan Graves' disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country's population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave's disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in…
Global Graves Disease Market Status and Outlook (2020-2025)
Global Info Research offers a latest published report on Graves Disease Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Graves Disease Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/515950/graves-disease
Market…
US Graves' disease Market Growth, Share, Trends & Forecast to 2025
US Graves' disease market is growing at a CAGR of around 4.0% during the forecast period. The US Grave's disease market is showing significant growth due to funding for autoimmune disease researches, and the increasing prevalence of hyperthyroidism in the region. In addition, significant rise in the prevalence of autoimmune disease is also expected to propel the growth of the US Graves' disease market. According to the American Autoimmune Related…
